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Abstract
AIM: To evaluate the benefit and effectiveness of MR-
arterioportography (MR-AP) to achieve the highest 
sensitivity for detection and evaluation of hepatocellu-
lar carcinoma (HCC).
METHODS: Twenty liver cirrhosis patients with sus-
pected HCC were included before transarterial chemo-
embolization. In all patients double-enhanced Magnetic 
resonance imaging (MRI) was performed. A bolus of 
10 mL Magnevist® was injected through a selectively 
placed catheter in the superior mesenteric artery and 
MRI of the liver was performed in arterioportographic 
phase. Two independent readers evaluated number, size 
and localization of detected lesions. Diagnostic quality 
was determined using a 4-point scale. Differences were 
analyzed for significance using a t -test. Interobserver 
variability was calculated. 
RESULTS: In all 20 patients (100%), MR-AP was feasi-
ble. Diagnostic quality was, in all cases, between 1 and 
2 for both modalities and readers. MR-AP detected sig-
nificantly more lesions than double-enhanced MRI (102.5 
vs  61, respectively, P  < 0.0024). The inter-observer 
variability was 0.881 for MRI and 0.903 for MR-AP. 
CONCLUSION: Our study confirmed that the MR-AP as 
an additional modality for detection of HCC is beneficial, 
as significantly more lesions were detected compared to 
MRI with liver-specific contrast.
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common 
primary malignant tumor of  the liver and often develops 
in patients with underlying liver cirrhosis due to exces-
sive alcohol intake, chronic hepatitis or primary biliary 
cirrhosis. 
In the treatment of  hepatocellular carcinoma, surgical 
resection is considered the only potentially curative ther-
apy. However, technical improvements in hepatic surgery 
have extended the indications for surgery remarkably, and 
also regional therapeutic procedures such as transcatheter 
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arterial chemoembolization (TACE)[1-3] and radiofrequen-
cy ablation (RFA)[1,4,5] have proved to be very successful. A 
prolonged time of  survival following diagnosis is noted. 
Therefore, the pre-operative or pre-interventional workup 
of  patients with suspected liver malignancy is even more 
important, especially concerning the evaluation and char-
acterization of  focal or diffuse lesions in the cirrhotic 
liver. Magnetic resonance imaging (MRI) has been used 
to improve identification of  focal hepatic masses in a cir-
rhotic liver.
Dynamic MRI after a bolus injection of  gadopentetate 
dimeglumine has been accepted as a valuable method 
for the detection and characterization of  liver tumors[6-9]. 
Studies have shown that superparamagnetic iron oxide-
enhanced magnetic resonance imaging (SPIO-MRI) in-
creases sensitivity[4,10]. 
In order to determine the treatment of  choice for HCC, 
studies have shown that examinations by both computed 
tomography angiography (CTA) and computed tomog-
raphy arterioportography (CT-AP) are indispensable 
because of  the high sensitivity of  CT-AP in detecting 
hepatic lesions and the capability of  CTA to characterize 
them[11,12]. However, in contrast to its high sensitivity in 
detecting lesions, the specificity of  CT-AP for character-
izing intrahepatic lesions is low. Tumor-mimicking benign 
perfusion abnormalities and benign lesions (e.g. heman-
giomas, arterio-venous shunts) have led to a reported in-
cidence of  false-positive lesions between 9% and 63% in 
primary and secondary liver lesions[13,14].
Despite advances in CT or MRI, ultrasound (US) with 
or without application of  contrast agents also plays a key 
role in the diagnostic algorithm of  HCC due to its low 
cost, availability and non-invasiveness.
Until now, there have hardly been any studies compar-
ing the effectiveness of  MR-arterioportography (MR-AP) 
and contrast-enhanced MRI for diagnosis of  malignant 
liver lesions. Thus, the purpose of  this study was to com-
bine the advantages of  modern contrast-enhanced MRI 
with the technique of  arterioportography to achieve the 
highest sensitivity for diagnosis of  malignant liver lesions 
in patients suffering from HCC.
MATERIALS AND METHODS
Patients
Approval for this study was obtained from the institu-
tional review board in conformity with the Declaration 
of  Helsinki. Before the procedures were conducted, 
written informed consent was obtained from each pa-
tient for MRI, MR-AP and angiography after the nature 
of  the procedure was fully explained.
During the period from February 2005 to September 
2007, 20 patients [18 men, 2 women, age range from 47 to 
76 years (mean age, 62 years)] with symptoms suggestive 
of  primary malignant hepatic tumors were referred to our 
department. As HCC is commonly associated with liver 
cirrhosis, all patients had deteriorated liver but a tolerable 
renal function, and the cardiovascular status was stable. 
Twelve of  our 20 patients suffered from alcohol toxic 
liver cirrhosis. In 4 out of  20 patients the underlying dis-
ease was chronic hepatitis (2 patients with chronic hepa-
titis B, 2 patients with chronic hepatitis C). In 4 out of  20 
patients, the fundamental disease could not be elicited. 
Concerning the severity of  cirrhosis, 8 out of  20 patients 
were classified as Child Pugh score A, 7 out of  20 patients 
as Child Pugh score B and 5 out of  20 patients as Child 
Pugh score C.
The existence of  malignant hepatic tumors was con-
firmed using multislice MRI and CT. MR-AP was per-
formed to evaluate the tumor extent in order to suggest 
interventional therapy, surgery or chemotherapy. 
Diagnosis of  HCC was histologically confirmed in 15 
out of  19 patients. In one patient (patient No. 16), exis-
tence of  a malignant hepatic lesion was excluded histo-
logically following liver transplantation.
In 13 out of  20 patients the a-fetoprotein (AFP) 
level was elevated, ranging from 16.4-2513 ng/mL (mean 
488.1 ng/mL). In 7 patients (including patient No. 16) AFP 
levels were within a normal range. 
Imaging procedures
Angiography: Before TACE and for MR-arteriopor-
tography, the femoral common artery was punctured 
under local anesthesia using the Seldinger technique and 
a 5-French angiographic catheter (Cobra, Cook Medical, 
USA) was positioned in the proximal superior mesenteric 
artery. A diagnostic angiography was performed to visu-
alize the portal vein and to exclude shunts which could 
involve contrasting via the portal vein.
MRI: MRI was performed on a 1.5-T whole-body scan-
ner (Magnetom Sonata, Siemens Medical Solutions, Ger-
many) equipped with a high-performance gradient (Quan-
tum) system (maximum gradient strength, 30 mT/m; slew 
rate, 125 T/ms). A combination of  the standard body 
phased-array coil with spine array coils was used for signal 
reception.
MR-AP standard protocol (Table 1): For MR-AP, 10 mL 
gadopentetate dimeglumine was injected through the cath-
eter placed in the superior mesenteric artery at a rate of  
2 mL/s with a power injector (Medrad Spectris MR Injec-
tor, USA).
MRI standard protocol (Table 2): For MRI, 0.2 mmol/
kg body weight gadopentetate dimeglumine was injected in-
travenously at a rate of  2 mL/s with a power injector (Me-
drad Spectris MR Injector). T1-weighted VIBE transversal 
Dynamic scans were acquired 20, 40, and 120 s after ap-
plication of  gadopentetate dimeglumine. T2-star-weighted 
Flash 2D scans and T2-weighted TSE FS scans were ob-
tained after application of  1.4 mL Ferucarbotran (Resovist®, 
Bayer Schering Pharma AG, Germany). 
Image analysis
In the retrospective reviewing procedure, all images of  each 
technique were interpreted and evaluated independently 
by two observers with great experience in abdominal MRI. 
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No clinical information or patient diagnosis was given to 
the observers. The images from each technique were inter-
preted in separate sessions in a randomized sequence. In 
the first session, the two observers reviewed a set of  images 
that included both unenhanced and gadopentetate dimeglu-
mine-enhanced, as well as Resovist-enhanced, images. 
In the second session, each observer reviewed a set of  
images (MR-AP set) that included gadopentetate dime-
glumine-enhanced images after injection via the superior 
mesenteric artery.
For characterization of  liver lesions, all images of  
each examination were reviewed together using all the 
sequences available. Each observer recorded the number 
of  suspected lesions noted, their size, and the segmental 
location. Furthermore, the image quality of  MR and 
MR-arterioportography was documented on a four point 
scale: 1-excellent, 2-minor diagnostic limitations, 3-major 
diagnostic limitations, 4-non-diagnostic.
Statistical analysis
Statistical software (SPSS, version 14, Chicago, USA) was 
used for statistical analysis. We evaluated the differences 
with regard to number of  lesions found using MR-arte-
rioportography and MRI. Furthermore, the inter-observ-
er differences in evaluation of  MR-arterioportography 
and double-enhanced MRI were analyzed. Paired-samples 
t tests and χ2 test were used to compare. In paired-
samples t tests, P < 0.05 indicated a statistically significant 
difference.
RESULTS
Twenty patients with liver cirrhosis underwent combined 
MR-arterioportography and SPIO-MRI examinations. 
No adverse reactions were experienced by any of  the pa-
tients who received Gd-DTPA and SPIO.
In all 20 patients (100%), MR-arterioportography was 
feasible. The image quality in both modalities (MR-AP 
and MRI) was excellent (1-2 in MR-arterioportography, 
SD: 0.4865; 1-2 in MR, SD: 0.4292). In patient No. 8, a 
MR-AP evaluation was not suitable due to a diffuse infil-
tration of  virtually all liver segments, thus the patient was 
excluded. Altogether, 102.5 hepatic lesions were detected 
using MR-AP, whereas only 61 lesions could be detected 
using MRI (Table 3). This difference is considered to be 
statistically significant (P < 0.0024).
The kappa analyses of  two observers regarding the 
number of  lesions detected by both modalities showed sub-
stantial to excellent agreement (κ = 0.903, 95% CI: 0.844 to 
0.962 for MR-AP; and κ = 0.881, 95% CI: 0.795 to 0.966 
for MRI). In particular, κ values with MR-AP imaging indi-
cated excellent agreement. 
The lesions found in all patients ranged in size from 
7-120 mm (mean 28.24 mm) for MRI and from 4-120 mm 
(mean 24.62 mm) for MR-AP. This difference is not con-
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Table 1  MR-arterioportography standard protocol
Scans Plane TE TR Flip angle
Unenhanced
   T2-weighted TRUFI Coronal     1.9     3.8 71°
   T2-weighted TRUFI Transversal 1.88 3.76 71°
   T1-weighted VIBE Transversal 2.02 4.78 10°
Enhanced
   T1-weighted FLASH FS CE Transversal 4.76 123 70°
   T1-weighted VIBE dynamic1 Transversal 2.02 4.78 10°
1Dynamic scans were started immediately following application of 10 mL 
Gd-DTPA. MRI: Magnetic resonance imaging.
Table 2  Magnetic resonance imaging standard protocol
Scans Plane TE TR Flip angle
Unenhanced
   T1-weighted VIBE Transversal     1.59       4.37   10°
   T2-star-weighted FLASH 2D Transversal   10.00   169.00   90°
   T2-weighted TSE FS Transversal 105.00 2740.00 170°
   T1-weighted FLASH opp Transversal     2.71   100.00   70°
   T1-weighted FLASH in Transversal     4.76     87.00   60°
   T2-weighted HASTE Transversal   85.00 1000.00 150°
   T2-weighted TRUFI Coronal     1.83       3.65   71°
   T1-weighted VIBE Transversal     1.55       4.81   10°
Enhanced
   T1-weighted VIBE dynamic1 Transversal     1.55       4.81   10°
   T1-weighted FLASH FS Transversal     4.76   123.00   70°
   T1-weighted FLASH FS Coronal     4.76     94.00   70°
   T2-star-weighted FLASH 22 Transversal   10.00   169.00   90°
   T2-weighted TSH FS2 Transversal 105.00 2740.00 170°
1Dynamic scans were started immediately following application of Gd-
DTPA (0.2 mmol/kg); 2Following application of 1.4 mL Resovist. 
Table 3   Number of lesions detected in MR-arterioportogra-
phy and magnetic resonance imaging
Patient Age (yr) MR-AP 
number of lesions 
∑102/103
Double-enhanced MRI 
number of lesions 
∑60/56
Reader 1 Reader 2 Reader 1 Reader 2
1 62 9 9 5 4
2 47 7 8 2 2
3 70 4 5 2 2
4 74 7 8 4 3
5 51 3 3 3 3
6 76 1 2 1 1
7 70 6 6 9 8
81 63 - - (7) (7)
9 70 4 4 2 2
10 63 9 8 2 2
11 51 9 8 6 5
12 63 10 11 3 2
13 57 6 6 2 2
14 67 5 4 4 5
15 51 4 3 3 2
16 53 0 0 1 1
17 51 2 2 2 2
18 54 5 6 3 3
19 57 9 8 4 4
20 73 2 2 3 3
1Patient No. 8 was excluded from the evaluation for diffuse infiltration of 
virtually all liver segments. P = 0.0024 (relation of the number of lesions 
detected in MR-AP and MRI). MR-AP: MR-arterioportography; MRI: Mag-
netic resonance imaging.
sidered to be statistically significant. In MRI, 16 lesions 
(26.2%) were 10 mm or less in diameter. In MR-AP, 30 
lesions (29.3%) were 10 mm or less in diameter.
In a total of  15 out of  19 patients, more lesions were 
detected by MR-AP compared to MRI with liver-specific 
contrast. According to the characteristic features dis-
played in MR-AP, all lesions were classified as malignant. 
Thus, as a consequence of  the finding of  these additional 
lesions, further treatment (TACE, RFA or surgery) was 
performed upon the patients.
In all but one patient (patient No. 16), the lesions 
found displayed a characteristic MRI signal, including ar-
terial enhancement to a greater or lesser extent, with late 
wash out and an absent accumulation of  Ferucarbotran 
(Resovist®). Thus, these lesions were classified as malig-
nant. In addition, these lesions also showed characteristic 
features in MR-AP, such as absent enhancement of  gado-
pentetate dimeglumine with profound demarcation com-
pared to healthy liver tissue. Hence, the lesions were also 
classified as malignant. 
Diagnosis of  HCCs was histologically confirmed in 15 
out of  19 patients. In patient No. 16, one lesion was found 
in segment 8 of  the liver which showed a portal venous 
enhancement with accumulation of  Ferucarbotran and no 
traceability in MR-AP. The lesion therefore was classified 
as benign, i.e. regenerated nodule that was confirmed his-
tologically following liver transplantation (Figures 1 and 2). 
DISCUSSION
Before decisions are made as to hepatic resection of  he-
patocellular carcinoma or interventional treatment such as 
TACE, percutaneous ethanol injection therapy and radio-
frequency ablation (RFA), accurate information regarding 
the number and localization of  lesions is essential. 
Because of  its high sensitivity for detecting lesions, 
CT-AP is one of  the most reliable tools for detection of  
liver lesions. The rationale of  CT-AP is for contrast mate-
rial to be delivered directly to the liver through the portal 
vein before it can return to the hepatic artery from the 
systemic circulation, to optimize the detection of  tumor 
lesions that do not have portal vein flow and appear as 
hypodense nodules. The aim of  our study was to com-
bine the advantages of  arterioportal contrast and MRI to 
detect liver lesions in patients with HCC. MRI with liver-
specific contrast agents is currently the imaging modality 
of  choice. Most studies that have directly compared MRI 
with CT-AP in patients with HCC or metastases reported 
no significant differences in sensitivity[15-17], but in some 
studies a higher specificity for MRI is reported[13]. 
 Preoperative or pre-interventional workup of  patients 
with suspected liver malignancy is even more important, 
especially concerning the evaluation and characterization 
of  a focal lesion or diffuse infiltration of  the cirrhotic liver. 
Previous studies have shown the usefulness of  feru-
moxide-enhanced MR imaging for the detection of  
hepatic tumors of  different histological types[18,19]. After 
intravenous injection, the SPIO-particles are cleared 
by macrophages and can be identified histologically in 
Kupffer’s cells of  the liver. Poorly differentiated hepatic 
tumors lack Kupffer’s cells; therefore, the T2 relaxation 
does not change after the administration of  SPIO causing 
an increased lesion-to-liver  contrast.
Studies of  patients with hepatic metastases have shown 
that ferumoxide-enhanced MR imaging is more sensitive 
than unenhanced MR imaging[20,21] or contrast-enhanced 
CT[22,23], and at least as accurate as CT during arteriopor-
tography[10]. 
Regarding the detection of  HCCs, it has been reported 
that the sensitivity of  combined CT during arterioportog-
raphy and CT hepatic arteriography is 89%-95%[24,25] in 
comparison to 80.4% on contrast-enhanced CT alone[26]. 
Furthermore, the sensitivity of  MR sequences with feru-
moxide enhancement was reported to be 78%-92%[18,19,24], 
and that of  MR-AP 94%-97%[27,28].
Diffusion-weighted imaging (DWI) is a MRI technique 
that provides imaging of  diffusion in biological tissues. 
Recent technical developments have reduced the image 
deformation associated with this technique and have in-
creased the signal to-noise ratio, thus making DWI of  the 
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Figure 1  A 49-year-old man with hepatic cirrhosis due to chronic hepatitis B and C infection. Histology obtained following liver transplantation confirmed the 
diagnosis of a multifocal hepatocellular carcinoma. A: Magnetic resonance imaging (T1-weighted VIBE) during early venous phase shows a low signal intensity nodule 
with a diameter of approximately 3 cm in segment Ⅷ/Ⅴ; B: SPIO-enhanced T2-weighted fast image shows an area of increased signal intensity (segment Ⅷ/Ⅴ) 
within the otherwise lower but very inhomogenous signal of the liver parenchyma with profound cirrhosis; C: MR-AP (T1-weighted VIBE) during early venous phase 
displays an area of decreased enhancement (approx. 4.5 cm diameter) in segment Ⅷ/Ⅴ. Note the multiple smaller hypointense lesions in segments Ⅶ/Ⅵ. SPIO: 
Superparamagnetic iron oxide-enhanced.
A B C
body feasible[29], especially for detection of  liver malignan-
cies[30]. Studies have reported a higher sensitivity of  DWI 
for detection of  small hepatic metastases compared to 
SPIO-enhanced T2-weighted images and breath-hold T2-
weighted images[31,32], particularly due to a profound signal 
intensity of  the HCC in the cirrhotic liver. In comparison, 
cysts and hemangiomas, the most frequently found benign 
lesions of  the liver, typically show low or absent signal in-
tensities[33].
Our study demonstrated that MR-arterioportography 
as an alternative method for detection of  HCC is not 
only feasible but showed a significantly larger number of  
lesions than ferumoxide-enhanced MR imaging, espe-
cially in patients with hepatic cirrhosis. 
Also, the lesion’s size seems to play a crucial role. Out 
of  the 41 lesions that were exclusively found using MR-AP, 
21 were 10 mm or less in diameter. This confirms the high 
sensitivity of  MR-AP, especially regarding smaller lesions. 
However, a definite differentiation among HCC nodules, 
regenerative dysplastic nodules or, for example, small arte-
rio-venous shunts that are very common in patients with 
hepatocellular carcinoma is not possible.
One limitation of  the study is that a histological confir-
mation of  HCC or benign lesions could only be obtained in 
16 out of  20 patients. In the other 4 patients, further treat-
ment was based upon the combination of  typical image 
morphology and elevated alpha fetoprotein. Another limi-
tation is the relatively small number of  patients that were 
examined in this study. Prospective studies are necessary in 
order to ascertain the diagnostic reliability of  MR-AP com-
pared to established methods.
In summary, our study confirmed that the use of  MR-
arterioportography as an additional modality for detec-
tion of  hepatocellular carcinoma is useful. Using this 
technique, significantly more lesions could be detected in 
comparison to MRI with liver-specific contrast agent.
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nosis of a well differentiated hepatocellular carcinoma. A: Magnetic resonance imaging (T1-weighted VIBE) during arterial phase shows a singular hyper-vascularized 
nodule with a diameter of approximately 2 cm in segment Ⅶ; B: T1-weighted VIBE during early venous phase shows an inhomogenous signal of the liver parenchyma 
with masking of the lesion in segment Ⅶ; C: SPIO-enhanced T2-weighted fast image shows an area of increased signal intensity (segment Ⅶ) within a low signal of 
the liver parenchyma; D: MR-AP (T1-weighted VIBE) during early venous phase displays an area of decreased enhancement (approx. 3 cm diameter) in segment Ⅶ
and various low signal lesions in segments Ⅰ, Ⅳa, Ⅷ and Ⅶ. SPIO: Superparamagnetic iron oxide-enhanced.
A B
C D
14 Soyer P, Bluemke DA, Hruban RH, Sitzmann JV, Fishman 
EK. Hepatic metastases from colorectal cancer: detection 
and false-positive findings with helical CT during arterial 
portography. Radiology 1994; 193: 71-74 
15 Kanematsu M, Hoshi H, Murakami T, Inaba Y, Kim T, 
Yamada T, Kato M, Yokoyama R, Nakamura H. Detection of 
hepatocellular carcinoma in patients with cirrhosis: MR im-
aging versus angiographically assisted helical CT. AJR Am J 
Roentgenol 1997; 169: 1507-1515 
16 Noguchi Y, Murakami T, Kim T, Hori M, Osuga K, Kawata 
S, Kumano S, Okada A, Sugiura T, Nakamura H. Detection 
of hepatocellular carcinoma: comparison of dynamic MR 
imaging with dynamic double arterial phase helical CT. AJR 
Am J Roentgenol 2003; 180: 455-460 
17 Semelka RC, Cance WG, Marcos HB, Mauro MA. Liver 
metastases: comparison of current MR techniques and spiral 
CT during arterial portography for detection in 20 surgically 
staged cases. Radiology 1999; 213: 86-91 
18 Tang Y, Yamashita Y, Arakawa A, Namimoto T, Mitsuzaki 
K, Abe Y, Katahira K, Takahashi M. Detection of hepatocel-
lular carcinoma arising in cirrhotic livers: comparison of 
gadolinium- and ferumoxides-enhanced MR imaging. AJR 
Am J Roentgenol 1999; 172: 1547-1554 
19 Yamamoto H, Yamashita Y, Yoshimatsu S, Baba Y, Hatana-
ka Y, Murakami R, Nishiharu T, Takahashi M, Higashida 
Y, Moribe N. Hepatocellular carcinoma in cirrhotic livers: 
detection with unenhanced and iron oxide-enhanced MR 
imaging. Radiology 1995; 195: 106-112 
20 Bellin MF, Zaim S, Auberton E, Sarfati G, Duron JJ, Khayat 
D, Grellet J. Liver metastases: safety and efficacy of detec-
tion with superparamagnetic iron oxide in MR imaging. 
Radiology 1994; 193: 657-663 
21 Fretz CJ, Elizondo G, Weissleder R, Hahn PF, Stark DD, 
Ferrucci JT Jr. Superparamagnetic iron oxide-enhanced MR 
imaging: pulse sequence optimization for detection of liver 
cancer. Radiology 1989; 172: 393-397 
22 Hagspiel KD, Neidl KF, Eichenberger AC, Weder W, Marincek 
B. Detection of liver metastases: comparison of superpara-
magnetic iron oxide-enhanced and unenhanced MR imaging 
at 1.5 T with dynamic CT, intraoperative US, and percutane-
ous US. Radiology 1995; 196: 471-478 
23 Ward J, Naik KS, Guthrie JA, Wilson D, Robinson PJ. Hepatic 
lesion detection: comparison of MR imaging after the admin-
istration of superparamagnetic iron oxide with dual-phase 
CT by using alternative-free response receiver operating 
characteristic analysis. Radiology 1999; 210: 459-466 
24 Choi D, Kim S, Lim J, Lee W, Jang H, Lee S, Lim H. Preop 
erative detection of hepatocellular carcinoma: ferumoxides-
enhanced mr imaging versus combined helical CT during 
arterial portography and CT hepatic arteriography. AJR Am J 
Roentgenol 2001; 176: 475-482 
25 Murakami T, Oi H, Hori M, Kim T, Takahashi S, Tomoda K, 
Narumi Y, Nakamura H. Helical CT during arterial portogra-
phy and hepatic arteriography for detecting hypervascular he-
patocellular carcinoma. AJR Am J Roentgenol 1997; 169: 131-135 
26 Dai Y, Chen MH, Fan ZH, Yan K, Yin SS, Zhang XP. Di-
agnosis of small hepatic nodules detected by surveillance 
ultrasound in patients with cirrhosis: Comparison between 
contrast-enhanced ultrasound and contrast-enhanced helical 
computed tomography. Hepatol Res 2008; 38: 281-290 
27 Hosch WP, Schmidt SM, Plaza S, Dechow C, Schmidt J, Ley 
S, Kauffmann GW, Hansmann J. Comparison of CT during 
arterial portography and MR during arterial portography in 
the detection of liver metastases. AJR Am J Roentgenol 2006; 
186: 1502-1511 
28 Yu JS, Kim KW, Lee JT, Yoo HS. MR imaging during arte-
rial portography for assessment of hepatocellular carcinoma: 
comparison with CT during arterial portography. AJR Am J 
Roentgenol 1998; 170: 1501-1506 
1744 April 7, 2011|Volume 17|Issue 13|WJG|www.wjgnet.com
Terminology
MR-AP is an MRI procedure where the contrast agent is injected through a 
catheter placed in the superior mesenteric artery.
Peer review
It is well-written and is novel work. 
REFERENCES
1 Hamm B, Thoeni RF, Gould RG, Bernardino ME, Lüning M, 
Saini S, Mahfouz AE, Taupitz M, Wolf KJ. Focal liver lesions: 
characterization with nonenhanced and dynamic contrast 
material-enhanced MR imaging. Radiology 1994; 190: 417-423 
2 Yamashita Y, Fan ZM, Yamamoto H, Matsukawa T, Yo-
shimatsu S, Miyazaki T, Sumi M, Harada M, Takahashi M. 
Spin-echo and dynamic gadolinium-enhanced FLASH MR 
imaging of hepatocellular carcinoma: correlation with histo-
pathologic findings. J Magn Reson Imaging 1994; 4: 83-90 
3 Yamashita Y, Hatanaka Y, Yamamoto H, Arakawa A, Mat-
sukawa T, Miyazaki T, Takahashi M. Differential diagnosis 
of focal liver lesions: role of spin-echo and contrast-enhanced 
dynamic MR imaging. Radiology 1994; 193: 59-65 
4 Semelka RC, Shoenut JP, Kroeker MA, Greenberg HM, Simm 
FC, Minuk GY, Kroeker RM, Micflikier AB. Focal liver dis-
ease: comparison of dynamic contrast-enhanced CT and T2-
weighted fat-suppressed, FLASH, and dynamic gadolinium-
enhanced MR imaging at 1.5 T. Radiology 1992; 184: 687-694 
5 Shibata T, Murakami T, Ogata N. Percutaneous microwave 
coagulation therapy for patients with primary and metastatic 
hepatic tumors during interruption of hepatic blood flow. 
Cancer 2000; 88: 302-311 
6 Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. 
Radiofrequency ablation of hepatocellular cancer in 110 pa-
tients with cirrhosis. Ann Surg 2000; 232: 381-391 
7 Ito K, Honjo K, Fujita T, Matsui M, Awaya H, Matsumoto T, 
Matsunaga N, Nakanishi T. Therapeutic efficacy of transcath-
eter arterial chemoembolization for hepatocellular carcinoma: 
MRI and pathology. J Comput Assist Tomogr 1995; 19: 198-203 
8 Kamada K, Nakanishi T, Kitamoto M, Aikata H, Kawakami 
Y, Ito K, Asahara T, Kajiyama G. Long-term prognosis of 
patients undergoing transcatheter arterial chemoemboliza-
tion for unresectable hepatocellular carcinoma: comparison 
of cisplatin lipiodol suspension and doxorubicin hydrochlo-
ride emulsion. J Vasc Interv Radiol 2001; 12: 847-854 
9 Seki T, Tamai T, Nakagawa T, Imamura M, Nishimura A, 
Yamashiki N, Ikeda K, Inoue K. Combination therapy with 
transcatheter arterial chemoembolization and percutaneous 
microwave coagulation therapy for hepatocellular carcinoma. 
Cancer 2000; 89: 1245-1251 
10 Senéterre E, Taourel P, Bouvier Y, Pradel J, Van Beers B, 
Daures JP, Pringot J, Mathieu D, Bruel JM. Detection of he-
patic metastases: ferumoxides-enhanced MR imaging versus 
unenhanced MR imaging and CT during arterial portogra-
phy. Radiology 1996; 200: 785-792 
11 Kim SR, Ando K, Mita K, Fuki S, Ikawa H, Kanbara Y, Imoto 
S, Matsuoka T, Hayashi Y, Kudo M. Superiority of CT arte-
rioportal angiography to contrast-enhanced CT and MRI in 
the diagnosis of hepatocellular carcinoma in nodules smaller 
than 2 cm. Oncology 2007; 72 Suppl 1: 58-66 
12 Kim SR, Imoto S, Ikawa H, Ando K, Mita K, Fuki S, Saka-
moto M, Kanbara Y, Matsuoka T, Kudo M, Hayashi Y. Well-
to moderately-differentiated HCC manifesting hyperattenu-
ation on both CT during arteriography and arterial portog-
raphy. World J Gastroenterol 2007; 13: 5775-5778 
13 Kondo H, Kanematsu M, Hoshi H, Murakami T, Kim T, 
Hori M, Matsuo M, Nakamura H. Preoperative detection of 
malignant hepatic tumors: comparison of combined meth-
ods of MR imaging with combined methods of CT. AJR Am 
J Roentgenol 2000; 174: 947-954 
Rennert J et al . MR-AP-a new method for detection of liver lesions
29 Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van 
Cauteren M. Diffusion weighted whole body imaging with 
background body signal suppression (DWIBS): technical 
improvement using free breathing, STIR and high resolu-
tion 3D display. Radiat Med 2004; 22: 275-282 
30 Kim T, Murakami T, Takahashi S, Hori M, Tsuda K, Naka-
mura H. Diffusion-weighted single-shot echoplanar MR im-
aging for liver disease. AJR Am J Roentgenol 1999; 173: 393-398 
31 Nasu K, Kuroki Y, Nawano S, Kuroki S, Tsukamoto T, 
Yamamoto S, Motoori K, Ueda T. Hepatic metastases: diffu-
sion-weighted sensitivity-encoding versus SPIO-enhanced 
MR imaging. Radiology 2006; 239: 122-130 
32 Parikh T, Drew SJ, Lee VS, Wong S, Hecht EM, Babb JS, 
Taouli B. Focal liver lesion detection and characterization 
with diffusion-weighted MR imaging: comparison with stan-
dard breath-hold T2-weighted imaging. Radiology 2008; 246: 
812-822 
33    Koyama T, Tamai K, Togashi K. Current status of body MR 
imaging: fast MR imaging and diffusion-weighted imaging. 
Int J Clin Oncol 2006; 11: 278-85
S- Editor  Sun H    L- Editor  Logan S    E- Editor  Ma WH
1745 April 7, 2011|Volume 17|Issue 13|WJG|www.wjgnet.com
Rennert J et al . MR-AP-a new method for detection of liver lesions
